These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 15323580

  • 21. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group.
    N Engl J Med; 2006 Nov 09; 355(19):1967-77. PubMed ID: 17093248
    [Abstract] [Full Text] [Related]

  • 22. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J, Yang S, Wu W.
    Transplant Proc; 2005 Mar 09; 37(2):903-5. PubMed ID: 15848570
    [Abstract] [Full Text] [Related]

  • 23. Alemtuzumab induction in renal transplantation.
    Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J, INTAC Study Group.
    N Engl J Med; 2011 May 19; 364(20):1909-19. PubMed ID: 21591943
    [Abstract] [Full Text] [Related]

  • 24. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.
    Chin Med J (Engl); 2012 Mar 19; 125(6):1135-40. PubMed ID: 22613543
    [Abstract] [Full Text] [Related]

  • 25. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.
    J Heart Lung Transplant; 1991 Mar 19; 10(6):901-11. PubMed ID: 1661608
    [Abstract] [Full Text] [Related]

  • 26. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Mestre M, Torras J, Alsina J.
    Am J Kidney Dis; 1992 Dec 19; 20(6):603-10. PubMed ID: 1462990
    [Abstract] [Full Text] [Related]

  • 27. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA, Khawand N, Aquino A, Ali A, Korb S.
    Am J Kidney Dis; 1989 Nov 19; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [Abstract] [Full Text] [Related]

  • 28. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, Zucker MJ, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1990 Nov 19; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [Abstract] [Full Text] [Related]

  • 29. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, Phillips MG.
    J Thorac Cardiovasc Surg; 1990 Apr 19; 99(4):716-24. PubMed ID: 2108282
    [Abstract] [Full Text] [Related]

  • 30. Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation.
    Kode R, Fa K, Chowdhury S, Ranganna K, Fyfe B, Stabler S, Damask A, Laftavi MR, Kumar AM, Pankewycz O.
    Clin Transplant; 2003 Aug 19; 17(4):369-76. PubMed ID: 12868995
    [Abstract] [Full Text] [Related]

  • 31. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C, Cristol JP, Chong G, Okamba A, Lorho R, Mion C, Mourad G.
    Transpl Int; 1994 Aug 19; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [Abstract] [Full Text] [Related]

  • 32. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study.
    Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA, Lage E, Manito N, Alonso-Pulpón L.
    Transplantation; 2006 Jun 15; 81(11):1542-8. PubMed ID: 16770243
    [Abstract] [Full Text] [Related]

  • 33. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B.
    BioDrugs; 2005 Jun 15; 19(1):39-46. PubMed ID: 15691216
    [Abstract] [Full Text] [Related]

  • 34. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
    Lorber MI, Fastenau J, Wilson D, DiCesare J, Hall ML.
    Clin Transplant; 2000 Oct 15; 14(5):479-85. PubMed ID: 11048993
    [Abstract] [Full Text] [Related]

  • 35. Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3.
    Kode RK, Kumar AM, Pankewycz O, Damask AM, Seirka D, Lam A, Phillips K, Ardron M, Brezin J, Chvala R, Kumar MS.
    Transplant Proc; 2001 Oct 15; 33(1-2):1268-9. PubMed ID: 11267286
    [No Abstract] [Full Text] [Related]

  • 36. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies.
    Castro MC, Araujo LM, Nahas WC, Arap S, David-Neto E, Ianhez LE.
    Transplant Proc; 2004 May 15; 36(4):874-6. PubMed ID: 15194299
    [Abstract] [Full Text] [Related]

  • 37. Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units.
    García Meseguer C, Vila López A, Luque de Pablos A, Vallo Boado A, Simon JM, Pediatric EOSS Study Group.
    Transplant Proc; 2003 Aug 15; 35(5):1697-8. PubMed ID: 12962762
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G, Gu J, Qiu J, Wang C, Fei J, Deng S, Li J, Huang G, Fu Q, Chen L.
    Exp Clin Transplant; 2013 Aug 15; 11(4):310-4. PubMed ID: 23121641
    [Abstract] [Full Text] [Related]

  • 39. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA.
    Circulation; 1990 Nov 15; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [Abstract] [Full Text] [Related]

  • 40. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM.
    Transplantation; 1993 Jan 15; 55(1):110-6. PubMed ID: 8380508
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.